Amiodarone as a First-Line Therapy for the Conversion of Atrial Fibrillation or Long-term Maintenance of Sinus Rhythm Once Cardioversion Has Been Achieved by Dwyer, Nicole Marie
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
8-15-2009
Amiodarone as a First-Line Therapy for the
Conversion of Atrial Fibrillation or Long-term
Maintenance of Sinus Rhythm Once
Cardioversion Has Been Achieved
Nicole Marie Dwyer
Pacific University
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Dwyer, Nicole Marie, "Amiodarone as a First-Line Therapy for the Conversion of Atrial Fibrillation or Long-term Maintenance of
Sinus Rhythm Once Cardioversion Has Been Achieved" (2009). School of Physician Assistant Studies. Paper 172.
Amiodarone as a First-Line Therapy for the Conversion of Atrial
Fibrillation or Long-term Maintenance of Sinus Rhythm Once
Cardioversion Has Been Achieved
Abstract
Background: Optimal, long-term drug strategies for cardioversion of atrial fibrillation (AF) and maintenance
of sinus rhythm (SR) have been controversial. Amiodarone is an old drug that is an effective class III
antiarrhythmic for both converting and maintaining sinus rhythm in patients with atrial fibrillation, however,
there have been few recent, blinded, randomized controlled studies comparing amiodarone to other
pharmacological agents to determine if it is an effective first-line therapy.
Hypothesis: Amiodarone when used as a first-line therapy is an effective pharmacological strategy for
converting atrial fibrillation or maintaining sinus rhythm in patients with AF.
Study Design: A systematic review of randomized controlled studies.
Methods: A thorough electronic search of multiple databases including EBSCO, Medline, OVID, and
PUBMED were conducted in the English language using “amiodarone,” “atrial fibrillation,” and “randomized
controlled studies” as MeSH headings. Inclusion criteria were randomized controlled studies that included
patients in all age groups with recent-onset, paroxysmal, persistent or chronic AF who were treated with either
intravenous or oral amiodarone compared to placebo or another antiarrhythmic medication. Exclusion
criteria were studies older than ten years that were not randomized controlled studies, amiodarone used in
conjunction with other therapies, and post-surgical cardiac patients with recent-onset atrial fibrillation.
Methodological quality of each study was evaluated using the JADAD score. Studies with a score of >3 were
considered to be of high quality and were included in the review.
Results: Eight studies met the inclusion criteria for this review. All but one study demonstrated amiodarone’s
efficacy in converting or maintaining sinus rhythm. The study comparing dofetilide to amiodarone for the
conversion of either recent-onset AF or atrial flutter (Af) at three hours, proved to be more effective than
amiodarone, with 35% of dofetilide patients converting to SR compared to only 4% in the amiodarone group
(p <0.001). In the study that evaluated conversion of either AF or Af to SR after 48 hours with ibutilide or
amiodarone, findings were similar to that of dofetilide, but when AF was the only rhythm evaluated, there was
no statistical difference between amiodarone and ibutilide at converting AF (69% vs. 77%, p = ns). However,
when rapid cardioversion was desired in patients with AF or Af, ibutilide was faster at converting patients to
SR compared to amiodarone (53.4 +/- 25.8 min vs. 492 +/- 186 min, p =0.000). Two studies evaluating the
efficacy of amiodarone versus sotalol in maintaining SR at one year demonstrated amiodarone’s superiority
over sotalol (p=0.002; AFFRIM substudy) and (p <0.001; SAFE-T study) respectively, but when patients
with ischemic heart disease were analyzed separately in the SAFE-T study, amiodarone was equally as
effective as sotalol 4 in this patient subgroup (p=0.053) Two studies comparing amiodarone to class I
antiarrhythmics including propafenone (AFFRIM substudy), or to propafenone and sotalol combined
(CTAF study), found that amiodarone was superior in maintaining SR after one year (p <0.001) and (p
<0.001) respectively, while in Kochaidakis et al comparing amiodarone to propafenone alone found no
statistically significant difference between them for the suppression of recurrent symptomatic AF (p = 0.44).
This finding was true only when adverse events were factored into the primary endpoint. Without adverse
events amiodarone was slightly more effective than propafenone, and was just shy of statistical significance (p
= 0.058). Three studies compared amiodarone to placebo for either maintaining SR or cardioverting AF. One
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/172
study found amiodarone was more effective than placebo in maintaining AF after one year (p <0.001; SAFE-T
study), and Vardas et al found amiodarone was more effective than placebo in converting patients to sinus
rhythm at the 30-day mark (OR 6.21%; 95% CI, 3.33 to 11.57; p < 0.0001). In contrast, the third study
comparing dofetilide to amiodarone or placebo found that amiodarone was no more effective than placebo
after 3 hours for cardioverting AF, where 4% of patients in the amiodarone group compared to 4% of patients
in the placebo group had cardioverted at three hours. The final study evaluating the efficacy of digoxin verses
amiodarone or sotalol in converting recent-onset AF to SR, found digoxin was inferior to amiodarone and
sotalol combined (p <0.05; RR 5.4.; 95% CI 1.5 to 19.2), while sotalol versus amiodarone showed no
statistical difference (p=0.23).
Conclusion: In all but one study, amiodarone proved to be an effective first-line medication for the conversion
or maintenance of sinus rhythm in patients with atrial fibrillation. However, its use as a first-line agent in
symptomatic recent-onset AF is less effective than either ibutilide or dofetilide when prompt time to
conversion is required. Amiodarone also proved to be more effective than sotalol in maintaining SR after one
year, and demonstrated superior effectiveness when compared to class I antiarrhythmics. When compared to
propafenone, amiodarone demonstrated either equal or superior effectiveness for maintaining SR at one year.
However, because propafenone is a class I-C antiarrhythmic, it is contraindicated in patients with underlying
structural heart disease, whereby amiodarone is a reasonable first-line alternative.
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Abstract 
 
Background:  Optimal, long-term drug strategies for cardioversion of atrial fibrillation 
(AF) and maintenance of sinus rhythm (SR) have been controversial. Amiodarone is an 
old drug that is an effective class III antiarrhythmic for both converting and maintaining 
sinus rhythm in patients with atrial fibrillation, however, there have been few recent, 
blinded, randomized controlled studies comparing amiodarone to other pharmacological 
agents to determine if it is an effective first-line therapy. 
Hypothesis: Amiodarone when used as a first-line therapy is an effective 
pharmacological strategy for converting atrial fibrillation or maintaining sinus rhythm in 
patients with AF.   
Study Design: A systematic review of randomized controlled studies. 
Methods: A thorough electronic search of multiple databases including EBSCO, 
Medline, OVID, and PUBMED were conducted in the English language using 
“amiodarone,” “atrial fibrillation,” and “randomized controlled studies” as MeSH 
headings. Inclusion criteria were randomized controlled studies that included patients in 
all age groups with recent-onset, paroxysmal, persistent or chronic AF who were treated 
with either intravenous or oral amiodarone compared to placebo or another 
antiarrhythmic medication. Exclusion criteria were studies older than ten years that were 
not randomized controlled studies, amiodarone used in conjunction with other therapies, 
and post-surgical cardiac patients with recent-onset atrial fibrillation. Methodological 
quality of each study was evaluated using the JADAD score. Studies with a score of >3 
were considered to be of high quality and were included in the review.  
Results: Eight studies met the inclusion criteria for this review. All but one study 
demonstrated amiodarone’s efficacy in converting or maintaining sinus rhythm. The 
study comparing dofetilide to amiodarone for the conversion of either recent-onset AF or 
atrial flutter (Af) at three hours, proved to be more effective than amiodarone, with 35% 
of dofetilide patients converting to SR compared to only 4% in the amiodarone group (p 
<0.001). In the study that evaluated conversion of either AF or Af to SR after 48 hours 
with ibutilide or amiodarone, findings were similar to that of dofetilide, but when AF was 
the only rhythm evaluated, there was no statistical difference between amiodarone and 
ibutilide at converting AF (69% vs. 77%, p = ns). However, when rapid cardioversion 
was desired in patients with AF or Af, ibutilide was faster at converting patients to SR 
compared to amiodarone (53.4 +/- 25.8 min vs. 492 +/- 186 min, p =0.000). Two studies 
evaluating the efficacy of amiodarone versus sotalol in maintaining SR at one year 
demonstrated amiodarone’s superiority over sotalol (p=0.002; AFFRIM substudy) and (p 
<0.001; SAFE-T study) respectively, but when patients with ischemic heart disease were 
analyzed separately in the SAFE-T study, amiodarone was equally as effective as sotalol 
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in this patient subgroup (p=0.053) Two studies comparing amiodarone to class I 
antiarrhythmics including propafenone (AFFRIM substudy), or to propafenone and 
sotalol combined (CTAF study), found that amiodarone was superior in maintaining SR 
after one year (p <0.001) and (p <0.001) respectively, while in Kochaidakis et al 
comparing amiodarone to propafenone alone found no statistically significant difference 
between them for the suppression of recurrent symptomatic AF (p = 0.44). This finding 
was true only when adverse events were factored into the primary endpoint. Without 
adverse events amiodarone was slightly more effective than propafenone, and was just 
shy of statistical significance (p = 0.058). Three studies compared amiodarone to placebo 
for either maintaining SR or cardioverting AF. One study found amiodarone was more 
effective than placebo in maintaining AF after one year (p <0.001; SAFE-T study), and 
Vardas et al found amiodarone was more effective than placebo in converting patients to 
sinus rhythm at the 30-day mark (OR 6.21%; 95% CI, 3.33 to 11.57; p < 0.0001). In 
contrast, the third study comparing dofetilide to amiodarone or placebo found that 
amiodarone was no more effective than placebo after 3 hours for cardioverting AF, where 
4% of patients in the amiodarone group compared to 4% of patients in the placebo group 
had cardioverted at three hours. The final study evaluating the efficacy of digoxin verses 
amiodarone or sotalol in converting recent-onset AF to SR, found digoxin was inferior to 
amiodarone and sotalol combined (p <0.05; RR 5.4.; 95% CI 1.5 to 19.2), while sotalol 
versus amiodarone showed no statistical difference (p=0.23).   
Conclusion: In all but one study, amiodarone proved to be an effective first-line 
medication for the conversion or maintenance of sinus rhythm in patients with atrial 
fibrillation. However, its use as a first-line agent in symptomatic recent-onset AF is less 
effective than either ibutilide or dofetilide when prompt time to conversion is required. 
Amiodarone also proved to be more effective than sotalol in maintaining SR after one 
year, and demonstrated superior effectiveness when compared to class I antiarrhythmics. 
When compared to propafenone, amiodarone demonstrated either equal or superior 
effectiveness for maintaining SR at one year. However, because propafenone is a class I-
C antiarrhythmic, it is contraindicated in patients with underlying structural heart disease, 
whereby amiodarone is a reasonable first-line alternative.  
Keywords: Atrial fibrillation, cardioversion, first-line therapy, antiarrhythmics 
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Introduction 
Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in 
clinical practice today, accounting for approximately five million physician office visits 
and 350,000 hospitalizations each year 1. It is estimated that 2.2 million people 
experience paroxysmal or persistent atrial fibrillation in the U.S. with direct expenditures 
for AF estimated at about U.S. $7 billion annually 2. Atrial fibrillation can occur alone, 
but is often associated with other co-morbidities such as, left ventricular dysfunction, 
structural cardiomyopathies, hypertension, coronary artery disease, heart failure, chronic 
obstructive pulmonary disease (COPD), and sleep apnea, and it can temporarily 
exacerbate or permanently worsen any of these conditions 3. It is well known that the 
incidence of AF increases with age with 50% of cases occurring in patients older than 75 
years 3. The impact will increase in significance as the U.S. population continues to age 
and as the healthcare burden and related costs attributable to the treatment of atrial 
fibrillation increases 3 . Establishing effective prevention and treatment of atrial 
fibrillation remains an urgent issue. However, the best treatment options have yet to be 
determined as advances in electrical and pharmacologic interventions are incorporated 
into recommendations 3.  
Pharmacological Cardioversion 
One of several treatment strategies is the restoration and maintenance of normal 
sinus rhythm using a pharmacological approach with antiarrhythmics indicated for AF. 
Arguments for this approach focus on prevention of electrical and structural remodeling 
of the myocardium that leads to sustained AF and subsequent left ventricular dysfunction, 
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hemodynamic instability, ischemic heart changes, and heart failure 3, 4. Additionally, AF 
increases the risk of ischemic stroke to approximately 5% per year, with death or severe 
neurologic deficit occurring in 50% to 70% of cases 5. The risk of stroke attributable to 
AF annually is 1.5% in patients 50 to 59 years old and rises sharply to 23.5% in those 
aged 80 to 89 years 3. To mitigate this risk, anticoagulation is the standard of care, 
however, this also increases the risk of major bleeding, especially in the elderly 
population in which AF is more likely to occur 3, 5, 6. Consequently, morbidity and 
mortality related to AF is significantly increased independent of underlying cardiac 
disease. The rationale, therefore, is prompt treatment of AF with either electrical or 
pharmacological cardioversion to sinus rhythm to prevent electrical and structural 
remodeling, to avoid the need for oral anticoagulation in patients for whom it would 
otherwise be appropriate, to prevent hospitalizations or lengthy hospital stays related to 
AF, and to improve overall patient compliance 6. 
Optimal, long-term drug strategies for cardioversion of AF and maintenance of 
sinus rhythm have been controversial. Each antiarrhythmic drug carries its own risk, and 
adverse effects must be weighed against the benefits. Furthermore, variables that depend 
on patient presentation and co-morbidities often determine the choice of drug. For 
example, class I-C antiarrhythmic agents such as propafenone are contraindicated due to 
their proarrhythmic effects in patients with structural heart disease 3. In contrast, 
amiodarone is an old drug that is an effective class III antiarrhythmic for both converting 
and maintaining sinus rhythm in patients with atrial fibrillation, and is not contraindicated 
in patients with underlying heart failure 3. Unfortunately, amiodarone has a side effect 
profile that involves many different organ systems. As many as 80% of patients 
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experience side effects ranging from minimal gastrointestinal symptoms such as nausea, 
vomiting, and diarrhea to the more severe thyroid abnormalities, and pulmonary and 
ocular toxicity 7. However, only 10% to 15% of patients require withdrawal of the drug 
due to serious toxicity 7. Regardless, these numbers make its use as a first-line therapy 
undesirable for many practitioners. Consequently, there have been few blinded, 
randomized controlled studies to determine if amiodarone is an effective initial 
monotherapy. The purpose of this systematic review is to evaluate the efficacy of 
amiodarone as a first-line therapy in the conversion or maintenance of normal sinus 
rhythm in patients with atrial fibrillation. 
Methods 
A thorough search of the literature was conducted from 1999 to 2009 using 
multiple electronic databases including EBSCO, Medline, OVID, and PUBMED. 
“Amiodarone,” “atrial fibrillation,” and “randomized controlled studies” were used as 
MeSH headings. Inclusion criteria were published, randomized controlled studies in the 
English language, which included patients in all age groups who had either recent-onset, 
paroxysmal, persistent or chronic AF, and who were treated with either intravenous or 
oral amiodarone compared to placebo or another antiarrhythmic medication. Exclusion 
criteria were studies older than ten years that were not randomized controlled studies, 
trials in which amiodarone was not used as a monotherapy, but in conjunction with other 
therapies, or if amiodarone was used in post-cardiac surgery patients with new onset 
atrial fibrillation. Methodological quality of each study was evaluated using the JADAD 
score (See table 1). Studies with a score of  >3 were considered to be of high quality and 
were included in the review. Furthermore, references from all primary studies, meta-
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analysis, and systematic reviews from the initial search were scrutinized to identify 
additional studies meeting the inclusion criteria that may have been missed in the first 
search. 
Results 
A search of over 200 articles yielded eight studies that met the inclusion and 
exclusion criteria for this systematic review (see table 2). All of the relevant studies 
located were prospective, randomized controlled studies ranging in publication dates 
from 2000-2006. Methods of randomization varied between studies with three studies 
using a computer-generated random number algorithm, three studies using a permuted-
block randomization method, and two studies not specifying randomization methods. The 
AFFIRM substudy did a second randomization of patients in the rhythm arm of the initial 
study to either amiodarone, sotalol, class I-A or I-B antiarrhythmic agents that included 
quinidine, procainamide, diospyramide, moricizine, or the class I-C agents, propafenone 
or flecanide.1 Only one study, the SAFE-T, was a double blinded study with the 
exception of Bianconi et al, which was double blinded when comparing dofetilide to 
placebo, but single blinded when comparing amiodarone to dofetilide or placebo. Five 
studies were single blinded, and the Canadian Trial of Atrial Fibrillation was an open 
label study. All studies had JADAD scores of greater than three, with two studies scoring 
a five, while the remaining six scored values of three. This was due largely to the fact that 
the remaining six studies were not double blinded, which inevitably introduces a 
modicum of bias. 
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Patient Characteristics 
Patient characteristics varied between studies depending on the endpoint of 
interest (see table 2). Patients in all eight studies were either currently in AF, or had a 
recent history of being in AF. Atrial fibrillation was defined as ‘paroxysmal’ when it 
terminates spontaneously, usually within 24 hours, ‘persistent’ when pharmacological or 
electrical cardioversion is effective in terminating AF, and ‘permanent’ when 
cardioversion fails or is not attempted 4. Three studies, Joseph et al, Kafkas et al, and 
Bianconi et al evaluated patients with recent-onset AF lasting <24, <48, and between two 
hours and six months respectively. One study, the SAFE-T, evaluated patients with AF 
lasting ≥72 hours and specifically excluded patients in paroxysmal AF or atrial flutter 
(Af). The remaining studies evaluated symptomatic patients with either recent-onset, 
paroxysmal, or persistent AF.  In all but two studies, which evaluated recent-onset AF 
<24 hours, patients were treated with anticoagulants prior to cardioversion as 
recommended by the American College of Cardiology (ACC ) guidelines to reduce the 
risk of thromboembolism, which is greatest when AF has been present for more than 48 
hours. Concerning evaluation of left ventricular function and heart failure, three studies 
excluded patients with New York Heart Association Class III or IV heart failure, three 
studies used left ventricular ejection fraction (LVEF) parameters of < 0.30-0.40 as 
exclusion criteria, one study used LV dysfunction, but did not quantify this characteristic, 
and the final study excluded patients with clinically unstable heart failure as a result of 
AF or atrial flutter (Af). Only one study allowed for patients with varying stages of heart 
failure, but failed to include this data when evaluating the results.8 A lack of uniform 
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comparisons between patient characteristics for overall ventricular function and stage of 
heart failure in this review likely introduces some variability in results between studies.6  
Endpoints and Outcomes 
Four studies measured conversion to sinus rhythm as the primary endpoint, with 
three of these studies measuring time to conversion as the secondary endpoint (see table 
3). Two studies specifically evaluated patients with recent-onset AF or Af <24 to 48 h, 
one study evaluated patients with symptomatic AF admitted to the emergency department 
(ED) or treated in an outpatient setting, and one study included AF or Af of varying 
duration from 2 hours to 6 months (see table 2). Joseph et al compared the efficacy of 
sotalol, amiodarone, and digoxin in terms of reversion or ventricular rate after 
discontinuation of the study drug, time of reversion, and numbers of adverse events in 
120 patients admitted to the ED with new-onset, rapid AF or atrial flutter (Af) lasting < 
24 hours. Evidence showed that patients treated with amiodarone or sotalol were 
significantly more likely to have reverted to sinus rhythm compared to the digoxin group 
at 48 hours (p < 0.05). It also found a significant reduction in time to reversion of sinus 
rhythm with sotalol (13.0 +/- 2.5 hours, p < 0.01) and amiodarone (18.1 +/- 2.9 hours, p < 
0.05) compared with digoxin (26.9 +/- 3.4 hours). Finally, the sotalol-treated patients 
demonstrated a markedly lower ventricular rate compared with digoxin and amiodarone 
at 24 and 48 hours (p<0.05). A follow-up time of 48 hours was monitored following 
administration of treatment. No patients were lost to follow-up and five patients had 
protocol violations and were excluded from further analysis.  
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In the second study, Kafkas et al evaluated 152 patients with AF or Af lasting 
between three and 48 hours in duration and compared intravenous amiodarone with 
intravenous ibutilide for termination of these atrial arrhythmias. Follow-up was 24 hours. 
In total, the conversion rate for the ibutilide group (n=56/AF, n=23/Af) was significantly 
higher than the amiodarone group (n=52/AF, n=23/Af) with 80% of patients in the 
ibutilide group successfully reverting to sinus rhythm compared to 57% in the 
amiodarone group (p = 0.0054). However, conversion rates for the two groups did not 
differ significantly when the arrhythmia analyzed was AF where 77% in the ibutilide 
group compared to 69% in the amiodarone group converted to sinus rhythm (p >0.05). 
Furthermore, conversion rates of amiodarone were significantly more effective when the 
arrhythmia was AF verses Af (69% vs. 29%, p = 0.000). Finally, termination time was 
significantly shorter with ibutilide than with amiodarone for AF (53.4 +/- 25.8 vs. 492 +/- 
186 min, p = 0.000). Each drug markedly lengthened the QTc interval, however, the 
average lengthening of the QTc interval was not significantly different between the two 
groups (p = ns).  
In the third study, Bianconi et al randomized 150 patients to either dofetilide 
(n=48), amiodarone (n=50), or placebo (n=52) and found that 17 of 48 (35%) patients 
given dofetilide had converted to SR within the three hour study period compared to two 
out of 50 patients (4%) in the amiodarone group (p <0.001), and two out of 52 patients 
(4%) in the placebo group. The mean time to conversion was measured in the secondary 
endpoint where patients taking dofetilide had a mean conversion time of 55+/- 15 
minutes after the infusion began, and 65% of dofetilide patients converted to SR within 
30 minutes. A greater percentage of patients responded to dofetilide if their arrhythmia 
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lasted <7 days (9 of 21; 43%) than those whose arrhythmia lasted >7 days (8 of 27; 30%), 
however, this did not show statistical significance (p=0.59). 
In the fourth study, Vardas et al randomized 208 patients with symptomatic AF to 
either amiodarone or placebo with conversion to AF as the primary endpoint. Patients 
were followed for a total of 30 days. All patients in this study were treated with digoxin 
for ventricular rate control. Intravenous loading doses were administered initially with 
oral dosing for maintenance thereafter. Findings suggested that amiodarone was more 
effective than placebo in converting patients to sinus rhythm at the 30-day mark where 87 
patients (80.5%) in the amiodarone group, and 40 patients (40%) in the placebo group 
had converted  (OR 6.21%; 95% CI, 3.33 to 11.57; p <0.0001). Thirty-eight percent of 
amiodarone patients and 25% of placebo patients converted to SR within the first hour 
(OR 1.84; 95% CI, 1.1 to 3.33; p <0.05). Another 25 patients in the amiodarone group 
and 15 in the placebo group converted to SR between one and 24 hours. Multivariate 
predictors of conversion, using a logistic regression analysis, found that treatment, left 
atrial size, and atrial fibrillation duration, were significant independent predictors for 
conversion to SR. Patients with new-onset AF and left atrial size <40 mm were more 
likely to revert to SR regardless of treatment, however, when treated with amiodarone the 
number of patients successfully converted to SR was 99.7% compared to 88.7% in the 
placebo group (p <0.0001). Conversely, in patients with persistent AF and left atrial size 
<40 mm, those treated with amiodarone had conversion rates of 99.1% compared to 
69.2% in the placebo group (p <0.0001), and in patients with chronic AF and left atrial 
size <40 mm, these values changed to 89.3% and 14.4% respectively (p <0.0001; see 
table 4).  
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The remaining four studies compared amiodarone to placebo, sotalol, 
propafenone, or class I antiarrhythmics and measured the time to recurrence of AF as the 
primary outcome. In all but one study amiodarone proved statistically superior to these 
medications in maintaining SR. P-values ranged from p < 0.001 to < 0.05. The Canadian 
Trial of Atrial Fibrillation (CTAF) found that the median length of time to recurrence 
with propafenone or sotalol was 98 days compared to 468 days in the amiodarone group 
(p < 0.001), and the probability of remaining in SR at one year without recurrence of AF 
was higher in the amiodarone group (69%) verses the propafenone or sotalol groups 
(39%, p < 0.001). For the patients in the amiodarone group, the hazard ratio for a 
recurrence of AF was 0.43 (95% CI, 0.32 to 0.63), which equates to a 57% reduction in 
the risk of recurrence 8. 
In the AFFIRM substudy, 410 patients were treated with amiodarone compared to 
sotalol or class I antiarrhythmics. The primary endpoint measured maintenance of sinus 
rhythm with no additional cardioversion while still taking the assigned drug at one year, 
and the number of antiarrhythmic-related deaths, making this the only study that included 
mortality as an end point. At one year, 62% of patients in the amiodarone group 
compared to 23% of patients in the class I group were still in normal sinus rhythm (p < 
0.001).1 Moreover, at one year, 60% of patients in the amiodarone group were still in SR 
compared to only 38% of patients in the sotalol group (p = 0.002). Amiodarone was also 
more effective than class I agents and sotalol at maintaining sinus rhythm at the end of 
the follow-up period of 3.84 +/- 1.3 years (p = 0.0114) and (p = 0.0003) respectively. 
Concerning antiarrhythmic deaths, more deaths occurred in patients randomized to the 
class I agents (26 patients) than to amiodarone (10 patients). In both cases the deaths 
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were more likely to occur after the assigned drug had been discontinued 9. No significant 
difference was noted in death rates between amiodarone and sotalol, or between sotalol 
and class I agents.  
In the SAFE-T study, 665 male patients with AF ≥72 hours were treated with 
amiodarone, sotalol, or placebo with the primary endpoint being the time to the first 
recurrence of AF after successful restoration of SR. Patients were followed for 12 to 54 
months. Amiodarone and sotalol proved to be statistically more effective than placebo in 
increasing the time to recurrence of AF after sinus rhythm had been restored (p < 0.001). 
The median time to recurrence of AF in the amiodarone group was 487 days compared to 
74 days in the sotalol group and 6 days in the placebo group. The SAFE-T study also 
found that amiodarone was six times as effective as sotalol in the intention to treat 
analysis and four times as effective in the analysis of the treatment actually received in 
maintaining SR. However, when ischemic heart disease was reviewed, the results for 
amiodarone were not statistically significant compared to those for sotalol in maintaining 
SR in the subset where the time to recurrence was 569 days in the amiodarone group and 
428 days in the sotalol group (p = 0.53).  
In the study by Kochiadakis et al comparing low dose oral amiodarone to 
propafenone in 146 patients with recurrent, symptomatic AF in which successful 
electrical or chemical cardioversion had been achieved, the primary analysis included 
adverse effects in the end point and found that amiodarone had no significant advantage 
over propafenone in maintaining sinus rhythm (p = 0.44). However, in the secondary 
analysis when adverse events were not figured in the data, the difference between the two 
drugs was just short of statistical significance (p = 0.058) with amiodarone appearing to 
 19 
be better than propafenone in women (p = 0.03) and in patients < 65 years old (p = 0.01). 
Additionally, in the amiodarone group, the average length of time to recurrence was 
significantly longer at 9.8 months compared to 3.8 months in the propafenone group, 
while the number of patients experiencing side effects and consequently discontinuing 
medication was higher in the amiodarone group (n = 12) verses the propafenone group (n 
= 2).  
 Follow-up and Adverse Events  
 Follow-up between studies varied markedly with the longest duration of 12 to 54 
months in the SAFE-T study and 3.84 +/- 1.3 years in the AFFIRM study, and the 
shortest follow-up times at 3 hours, 24 hours and 48 hours in Bianconi et al, Joseph et al, 
and Kafkas et al respectively. The most common adverse events (AE) experienced in 
patients taking either oral or intravenous amiodarone were minor bleeding 10, hypotension 
5, 11, localized infusion reactions 5, 11, 12, GI disturbances 8, 11, 13, thyroid dysfunction 8, 13, 
and pulmonary toxicity 8-10. In the SAFE-T study, there were no significant differences in 
the rates of adverse events among study groups except rates of minor bleeding, which 
were significantly higher in the amiodarone group compared to sotalol and placebo 
combined (p < 0.04). Mortality between all three groups also did not differ significantly, 
with a death rate of 4.36 per 100 person-years’ follow-up in the amiodarone and sotalol 
groups combined compared to 2.84 per 100 person-years’ of follow-up in the placebo 
group (P = 0.13). In Vardas et al no patients were lost to follow-up after 30 days and no 
adverse events requiring discontinuation of the study medication occurred. Minor events 
included a significant drop in systolic blood pressure (SBP) within the first hour of 
amiodarone infusion in 12 patients, and phlebitis occurring at the infusion site in 17 
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amiodarone patients. In the AFFIRM substudy, there was no difference in adverse events 
requiring discontinuation of the study drug between the amiodarone patients (12.3%) and 
the sotalol patients (11.1%), however, this percentage was comparatively higher in 
patients taking class I antiarrhythmics (28.1%). Death due to arrhythmias was more likely 
to occur in patients taking class I agents compared to both amiodarone and sotalol 
combined. In the study by Kochiadakis et al, patients taking amiodarone had more 
adverse effects than those taking propafenone where 14 out of 17 patients experienced 
thyroid problems in the amiodarone group. While the authors noted those taking 
propafenone had fewer incidences of side effects, statistical analysis was not enumerated 
for comparison 13. No deaths occurred in this study. In the CTAF study, a total of 36 
patients in the amiodarone group (18%), compared to 23 patients in the combined sotalol 
and propafenone groups (11%) discontinued the study drug due to adverse events (p = 
0.06). The incidence of cardiac events requiring permanent discontinuation of the study 
drug was similar in the two groups where patients experiencing ventricular tachycardia, 
QTc prolongation, heart failure, and bradyarryhthmias were similar. The incidence of 
mortality was essentially the same between groups in which nine patients in the 
amiodarone group died compared to a combined eight patients in the sotalol or 
propafenone groups. 
The final three studies by Bianconi et al, Joseph et al, and Kafkas et al, had 
follow-up durations of 3h, 24h, and 48 hours respectively, where side effects directly 
related to amiodarone are less likely to occur because of the relatively slow 
pharmacokinetic properties of this drug 7, 14. Joseph et al found that patients taking 
digoxin versus sotalol or amiodarone were more likely to experience left ventricular heart 
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failure (six patients treated with digoxin compared to two treated with amiodarone, p 
<0.05), and hypothesized that this was probably due to poor rate control with digoxin 
over the other two agents. No episodes of hypotension were reported, and only one 
patient in the amiodarone group experienced thrombophlebitis. In the study conducted by 
Kafkas et al, ibutilide was more likely to cause ventricular arrhythmias such as torsades 
des points (n=3), premature ventricular beats (9% compared to 3% in the amiodarone 
group, p = ns), and non-sustained ventricular tachycardia (10 patients compared to 2 in 
the amiodarone group, p = 0.033). Two patients in the amiodarone group had 
hypotension, and five patients had localized infusion reactions. Bianconi et al had similar 
findings of torsades des pointes in 8% of patients treated with dofetilide, and an 
additional four dofetilide-treated patients experienced either isolated non-sustained 
ventricular tachycardia (n=2), premature ventricular beats with frequent couplets (n=1), 
or prolongation of the QT interval from 439 ms to 577 ms. Only one patient experienced 
an episode of mild hypotension that lasted for 13 minutes after the start of the infusion.  
Discussion 
  In all but one study, the results of this systematic review found that amiodarone 
was an effective first-line therapy in both converting atrial fibrillation to sinus rhythm or 
maintaining patients in sinus rhythm after they have been cardioverted regardless of the 
type of AF they presented with. However, not all atrial fibrillation responds the same way 
to amiodarone, where its overall success is influenced by a number of factors such as the 
duration of AF, underlying structural heart disease, age, and gender 3, 4. 
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In recent-onset AF, the more selective class III antiarrhythmics, ibutilide and 
dofetilide, proved to be superior alternatives to amiodarone for rapid conversion of AF. 
This is likely due to amidarone’s complex pharmacokinetics involving multiple 
compartments of distribution, hepatic breakdown of the parent drug into its active 
metabolite, and a long half-life, all of which slow its effects 15. Kafkas et al found that 
although amiodarone was as effective as ibutilide at converting AF to SR, ibutilide 
proved to be faster with a mean conversion time of 2.2 days compared to a mean of 20.5 
days with amiodarone (p = 0.000). In contrast, Bianconi et al found dofetilide to be 
superior to amiodarone or placebo at converting either AF or Af to SR where 35% of 
patients taking dofetilide converted to SR within the first three hours compared to only 
4% in the amiodarone group (p <0.001) and 4% in the placebo group. The mean time to 
conversion for dofetilide was 55 +/-15 minutes after the infusion began with 65% of 
patients converting to SR within 30 minutes. Although amiodarone showed no benefit 
over placebo for conversion to SR in this study, the follow-up time was only three hours, 
which was probably insufficient to capture the overall efficacy of amiodarone 6.  
Regardless, when prompt pharmacological cardioversion is required, the selective class 
III antiarrhythmics appear to be more effective than amiodarone in converting recent-
onset AF. 
While these findings are promising for symptomatic patients who require 
immediate cardioversion, care must be taken to monitor for the proarrhythmic effects of 
these drugs 14. Kafkas et al found a higher incidence of arrhythmias in patients treated 
with ibutilide compared to amiodarone in which torsades des pointes occurred in 3.8% of 
patients in the ibutilide group with none in the amiodarone group, and another ten 
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patients experienced monomorphic non-sustained ventricular tachycardia in the ibutilide 
group compared to only two in the amiodarone group (p =0.033).  Similarly, Bianconi et 
al also found a higher incidence of torsades des pointes in patients treated with dofetilide 
where 8% of patients experienced this arrhythmia. Neither of these studies had 
arrhythmia-related deaths, and the arrhythmias were successfully terminated in all 
patients. This clearly highlights some of the precautions needed when administering these 
drugs. In addition, dofetilide is primarily cleared through the kidneys and can be 
nephrotoxic in patients with kidney disease. The FDA requires providers to be certified in 
the dosing and administration of dofetilide, and patients must be hospitalized for a 
minimum of three days to monitor kidney and heart function 14. While the benefit of their 
rapid action demonstrates their superiority over amiodarone in the acute and symptomatic 
presentation of AF, risk of dangerous ventricular arrhythmias, and the added cost of 
administering the drugs must be weighed against their benefits 14. 
The duration of AF, and the presence of underlying structural heart disease are 
powerful predictors of successful cardioversion to SR in patients with AF 3, 4 . This is 
likely due to electrical remodeling that promotes AF in patients with cardiomyopathies 
and heart failure.3 These patients are less likely to convert to SR on their own and may 
require pharmacological intervention.4 This was illustrated in the study by Vardas et al 
where amiodarone was compared to placebo in patients with symptomatic AF, regardless 
of the type of AF, and followed for 30 days to evaluate efficacy of converting AF and 
maintaining SR at the 30-day mark. In the first 24 hours, patients with an initial 
intravenous loading dose of amiodarone and subsequent oral dosing experienced higher 
conversion rates and longer periods of maintained SR than the placebo group. Overall, 
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after a total of 30 days, conversion rates with amiodarone were 80.5% compared to 40% 
in the placebo group (p <0.0001), but in patients with a very large left atrium >46 mm 
and chronic AF, these rates fell to 61% and 34.6% respectively. In the placebo group, 
these percentages dropped sharply to 9.7% in patients with left atrium size >46 mm, and 
no patients in chronic AF converted to sinus rhythm. These findings illustrate the benefit 
of amiodarone over placebo in patients with longer-duration AF and underlying structural 
heart disease. Furthermore, amiodarone becomes a reasonable alternative to class I-C 
agents such as propafenone in which their use is contraindicated in patients with 
structural heart disease due to their proarrhythmic effects 3, 6, 14. 
In the SAFE-T, CTAF, AFFIRM substudy and the study by Kochiadakis et al, 
where the primary endpoint measured was the time to recurrence of AF after SR had been 
restored, all studies demonstrated amiodarone’s superiority over placebo, sotalol, 
propafenone, and class I-C antiarrhythmic agents in maintaining SR at one year. 
However, there were several exceptions to this finding. First, the study by Kochiadakis et 
al comparing low dose propafenone to amiodarone in maintaining SR, found amiodarone 
to be superior to propafenone with an average time to recurrence of 9.8 months in 25 
patients treated with amiodarone compared to only 3.8 months in 33 patients treated with 
propafenone. However, when adverse events were analyzed in the primary endpoint, 
equal efficacy was demonstrated between medications. They concluded that the 
advantage of amiodarone over propafenone in maintaining AF was offset by its side 
effect profile 13. Furthermore, they found amiodarone to be superior to propafenone in 
female patients and patients ≤ 65 years of age with AF, indicating that both female 
gender and a younger age may predict a more favorable outcome for conversion to SR 
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when amiodarone is chosen over propafenone. Second, in the SAFE-T study, 
investigators were surprised to find that in subgroups of patients with ischemic heart 
disease, amiodarone and sotalol were equally as effective at maintaining SR after one 
year (p = 0.53). Further studies to measure the efficacy of antiarrhythmic medications in 
patients with ischemic heart disease and are needed to evaluate these findings. 
Concerning adverse events, findings in this systematic review were difficult to 
compare between studies given the differences in AF type, variation in patient 
characteristics such as left atrial size and the presence or absence of underlying structural 
heart disease, and lengths of follow-up time. The SAFE-T and AFFIRM substudy had 
follow-up times of a minimum of one year and a maximum of 54 months and 3.84 +/- 1.3 
years respectively, and each study had similar patient characteristics. Both studies 
demonstrated no statistical difference in adverse events between amiodarone and sotalol, 
however, in the AFFIRM substudy, amiodarone and sotalol were significantly less likely 
to cause adverse events or death compared to class I agents. In contrast, the CTAF study 
found that 18% of patients in the amiodarone group compared to 11% in the combined 
sotalol and propafenone groups, discontinued the study drug due to adverse events (p = 
0.06), however, serious events with amiodarone were uncommon and no proarrhythmic 
events occurred. In Joseph et al comparing amiodarone to digoxin or sotalol for 
cardioversion of recent–onset AF with rapid ventricular response, patients treated with 
digoxin were more likely to experience left ventricular (LV) heart failure (six treated with 
digoxin and two treated with amiodarone) compared to amiodarone and sotalol 
combined. When these patients were evaluated for LV dysfunction with echocardiogram, 
two patients in the digoxin group and two patients in the amiodarone group already had 
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pre-existing LV dysfunction. The authors concluded that the remaining four patients in 
the digoxin group who experienced heart failure likely had poor rate control 5. This 
finding is interesting given the fact that digoxin is primarily indicated for rate control in 
rapid AF 14.  
The safety profile of amiodarone has created a great deal of apprehension in the 
medical community concerning its use. However, in this systematic review, when 
compared to other pharmacological agents, amiodarone demonstrated less proarrhythmic 
effects than the alternative class III agents, lower adverse events and mortality rates 
compared to class I agents, and was less likely to result in heart failure compared to 
digoxin. The most commonly experienced events specific to amiodarone were pulmonary 
toxicity occurring in four patients in the CTAF and AFFIRM substudy respectively, and 
in two patients in the SAFE-T study. None resulted in death. In Kochaidakis et al, thyroid 
dysfunction occurred in 14 patients resulting in discontinuation of the study drug, while 
GI disturbances were fairly common and easily mitigated by dose reduction or splitting 
of the dosage. Finally, in patients treated with intravenous amiodarone, hypotension was 
common and occurred in 12 patients in Vardas et al, five patients in Kafkas et al, and one 
case of mild hypotension in Bianconi et al. It is speculated that the mechanism for this is 
partially due to the effects of polysorbate 80, the solvent present in conventional 
amiodarone intravenous preparations, which is known to cause hypotension 4. 
Differences concerning the incidence of adverse events in this review leave unanswered 
questions regarding the overall safety of amiodarone as a first-line agent in the treatment 
of AF. However, its demonstrated efficacy over placebo in this review is undisputed, and 
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its potential efficacy over sotalol, propafenone, and other class I agents warrant the 
consideration of its use as a first-line therapy in the management of AF. 
Conclusion 
In all but one study of this systematic review, the data showed that amiodarone 
was effective as a first-line therapy in either the conversion of AF or the maintenance of 
SR. However, the duration of AF, presence of structural heart disease, age, and gender 
were influential in its overall success. In recent-onset AF, amiodarone was less effective 
than the class III antiarrhythmics ibutilide and dofetilide when rapid cardioversion was 
desired. Both medications proved superior to amiodarone in the time to conversion of 
AF, but each had a higher occurrence of proarrhythmias, which required continuous 
electrical monitoring and limited their use to the hospital setting. Furthermore, dofetilide 
can be nephrotoxic requiring several days of inpatient monitoring, thereby adding to the 
initial cost of treatment. When treating AF of longer duration where underlying structural 
heart disease is present, amiodarone is a relatively safe and effective alternative to class I-
C antiarrhythmics such as propafenone, and may be considered as a first-line therapy for 
conversion of AF to SR in this patient demographic. Amiodarone proved to be superior to 
sotalol at increasing the time to recurrence of AF, except in patients with ischemic heart 
disease where equal efficacy was demonstrated in this patient subgroup. Further studies 
are needed to evaluate this finding. Adverse events related to amiodarone were few, but 
serious events such as pulmonary toxicity and thyroid abnormalities do occur, and may 
be prevented through regular screening. Regardless, the incidence of serious adverse 
events with amiodarone are minimized by its beneficial effects, and in the right patient, 
amiodarone is an appropriate first-line therapy for the management of AF. 
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Table 1. JADAD Score Calculation* 
 
* Adapted from (Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports 
of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 
1996;17[1]:1-12 
 
 
 
 
 
 
 
Item Score 
Was the study described as randomized?  0/1 
Was the method used to generate the sequence of randomization described 
and appropriate (table of random numbers, computer-generated, etc)? 
0/1 
Was the study described as double blind? 0/1 
Was the method of double blinding described and appropriate (identical 
placebo, active placebo, dummy, etc)? 
0/1 
Was there a description of withdrawals and dropouts? 0/1 
Deduct one point if the method used to generate the sequence of 
randomization was described and it was inappropriate (patients were 
allocated alternately, or according to date of birth, hospital number, etc.)? 
0/-1 
Deduct one point id the study was described as double blind but the method 
of blinding was inappropriate (e.g., comparison of tablet, vs. injection with 
no double dummy). 
0/-1 
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TABLE 2. Studies Included in Systematic Review 
Abbr: AF (atrial fibrillation), Af (atrial flutter), CHF (congestive heart failure), ED (emergency department), HB (heart block), HF (heart 
failure), LVEF (left ventricular ejection fraction), NYHA (New York Heart Association). 
 
 
 
 
 
Study 
Authors 
Singh BN, et 
al. SAFE-T 
study 
AFFIRM substudy 
investigators 
Roy D, et al. 
CTAF study 
Kochiadakis 
GE, et al. 
Vardas PE, 
et al. 
Joseph AP, 
et al. 
Kafkas NV, 
et al. 
Bianconi L, et al. 
Study 
Design 
Double blind, 
placebo 
controlled, 
permuted 
block 
randomization 
Single blind, RCT Prospective, 
non-blinded, 
RCT 
Single blind, 
RCT 
Single blind, 
RCT 
Single 
blind, RCT 
Single blind, 
RCT 
Double blind for 
dofetilide/placebo 
and single blind 
for amiodarone, 
RCT 
JDAD 
Score 
5 3 3 3 3 3 3 5 
Study 
Year 
2005 2003 2000 2004 2000 2000 2006 2000 
Patient 
Population 
and 
Eligibility 
N=665 male 
patients with 
AF≥72h seen 
in outpatient 
clinics 
(excludes 
paroxysmal 
AF) 
N=410 with recent-
onset, paroxysmal, 
or persistent AF 
N=403 with 
at least one 
episode of 
symptomatic 
AF within 
last 6 months 
that lasted for 
>10 minutes 
N=146 with 
recurrent 
paroxysmal or 
persistent 
symptomatic 
AF in which 
successful 
chemical or 
pharmacological 
cardioversion 
had been 
achieved 
N=208 with 
symptomatic 
AF seen in 
ED or 
outpatient 
clinic 
N=120 with 
recent-onset 
AF or Af 
<24h 
admitted to 
the ED 
N=152 (103 
male, 49 
female) with 
symptomatic 
AF or Af of 
3 to 48h 
admitted to 
the ED 
N=150 with AF 
or Af of 2h to 6 
months duration 
Exclusion 
Criteria 
Atrial flutter, 
paroxysmal 
AF. NYHA 
class III/IV. 
Hx of long 
QT-syndrome 
Amiodarone/Sotalol: 
NYHA class ≥ II or 
HF with LVEF 
≤0.30, or ≤0.25 
alone. 
Disopyramide: 
LVEF ,0.30 
Class I-C: CHF, 
structural heart 
disease, LVEF 
<.0.50 
AF >  6 
months, 
NYHA 
≥II/IV. Hx of 
long QT 
syndrome or 
2nd or 3rd HB. 
ECG confirmed 
LVEF <0.40 
and structural 
heart disease. 
Severe HF 
LVEF 
≤0.30. Hx of 
2nd or 3rd 
degree HB 
or sick sinus 
syndrome 
AF >24 
days & 
present 
within last 7 
days. LV 
dysfunction. 
QTc >450 
ms.. 
Clinically 
unstable HF. 
Known sick sinus 
syndrome, or 2nd 
or 3rd degree HB. 
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TABLE 3. Endpoints and Outcomes (p-values) 
Study 
Authors 
Singh BN, et 
al. SAFE-T 
study 
AFFIRM 
substudy 
investigators 
Roy D, et al. 
CTAF study 
Kochiadakis 
GE, et al. 
Vardas PE, 
et al. 
Joseph AP, 
et al. 
Kafkas NV, 
et al. 
Bianconi L, 
et al. 
Drugs 
Compared 
1.Amiodarone 
vs. placebo 
2.Amiodarone 
vs. sotalol 
1.Amiodarone 
vs. sotalol 
2.Amiodarone 
vs. class I-C 
3.Sotalol vs. 
class I-C 
4.Amiodarone 
vs. class I-C 
vs. sotalol 
 
Amiodarone 
vs. sotalol or 
propafenone 
Amiodarone 
vs. 
propafenone 
Amiodarone 
vs. placebo 
Digoxin vs. 
amiodarone 
or sotalol 
Ibutilide vs. 
amiodarone 
Dofetilide 
vs. 
amiodarone 
or placebo 
Endpoints First 
recurrence of 
AF after SR 
restored.  
Secondary: 
Changes in 
quality of life 
scores. 
Composite: 
Patients alive, 
on drug, in SR, 
and no 
cardioversions 
at 4 months 
and 1 year. 
Also number 
of arrhythmic 
–related deaths 
Length of 
time to 
recurrence of 
AF. 
Lowest 
effective 
dose that 
could 
maintain SR 
at one year 
without 
producing 
AE. 
Conversion 
to SR after 
30 days. 
Conversion 
to SR within 
48h, and if 
not in SR, 
then 
ventricular 
rate.  
Secondary 
endpoint: 
time to 
conversion 
and AE 
Conversion to 
SR and up to 
4h following 
conversion, 
but <24 
hours. 
Secondary: 
Time to 
conversion 
Conversion 
to SR after 
3h. 
Secondary: 
Time to 
conversion 
P-values* Amiodarone & 
sotalol vs. 
placebo (p 
<0.001) 
Amiodarone 
vs. sotalol (p 
<0.001)  
Amiodarone 
vs. sotalol in 
pts with 
ischemic heart 
disease (p = 
0.53) 
 
Amiodarone 
vs. sotalol (p = 
0.002) 
Amiodarone 
vs. Class I-C 
(p <0.001) 
Deaths: class I 
agents (n=26) 
and 
amiodarone 
(n=10) 
Amiodarone 
vs. sotalol or 
propafenone 
(p <0.001). 
Amiodarone 
vs. 
propafenone 
(p = 0.44). 
Without AE 
analyzed in 
the endpoint 
(p = 0.058). 
Amiodarone 
vs. 
propafenone 
in women (p 
= 0.03) and 
age ≤65 (p = 
0.01) 
Amiodarone 
vs. placebo 
(OR 6.21; 
95% CI, 
3.33 to 
11.57; p 
<0.0001) 
Amiodarone 
or sotalol 
vs. digoxin 
(p <0.05). 
Time to 
conversion 
with sotalol 
or 
amiodarone  
(13.0 +/-
2.5h; 
p<0.01) and 
(18.1 =/-
2.9h; p 
<0.05) 
respectively 
vs. digoxin 
(26.9+/-
3.4h). 
Ibutilide vs. 
amiodarone 
when AF or 
Af (p = 
0.0054).When 
AF only, 
ibutilide vs. 
amiodarone 
(p > 0.05). 
Conversion 
rates of 
amiodarone 
for AF vs. Af 
(69% vs. 
29%, p = 
0.000) 
Time to 
conversion 
ibutilide vs. 
amiodarone 
(53.4+/-25.8 
vs. 492+/-186 
minutes, p = 
0.000). 
Dofetilide 
vs. 
amiodarone 
(p <0.001) 
 
Amiodarone 
vs. placebo 
(P = ns). 
Time to 
conversion: 
dofetilide 
55+/-15 
minutes; 
amiodarone 
not 
measured 
Abbr: AE (adverse events), AF (atrial fibrillation), Af (atrial flutter), SR (sinus rhythm). *If the drug is listed first the corresponding p-value 
indicates that drugs efficacy over the comparison drug. 
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Table 4.* Multivariate Predictors of Conversion to AF—Amiodarone Verses Placebo 
*Table adapted from Kochaidakis et al. Abbr: AF (Atrial fibrillation) 
Type of AF 
Left Atrium <40mm  Left Atrium 40-46mm  Left atrium >46mm 
Placebo Amiodarone Placebo Amiodarone Placebo Amiodarone 
Recent-onset AF 88.7%  99.7% (p < 
0.0001) 
36.3% 96.6% 27.9% 95.1% 
Persistent AF 69.2% 99.1% (p  
<0.0001) 
14.1% 88.9% 9.9% 84.5% 
Chronic AF 14.4% 89.3% (p 
<0.0001) 
1.2% 37.7% 0.8% 29.1% 
